Aspen Neuroscience to Present at 2023 Cell & Gene Meeting on the Mesa
SAN DIEGO, Oct. 9, 2023 /PRNewswire/ — Aspen Neuroscience announced today that Chief Technology Officer Kim Raineri and Chief Scientific Officer Xiaokui Zhang, Ph.D. will present at the annual Cell & Gene Meeting on the Mesa, held this week in Carlsbad, Calif. and live-streamed globally. CTO Kim Raineri will…
Dr. Andres Bratt-Leal to Present Preclinical Safety and Efficacy Data for ANPD001 at the 2023 World Parkinson Congress in Barcelona
SAN DIEGO, June 29, 2023 /PRNewswire/ — Next week at the upcoming World Parkinson Congress (WPC) 2023 in Barcelona, Spain, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President, Research and Development, will present preclinical safety and efficacy data for the first time for…
Chief Scientific Officer Xiaokui Zhang Profiled in Insights Care Magazine
Our Chief Scientific Officer, Xiaokui Zhang, PhD, was profiled in the Insights Care article titled, “Xiaokui Zhang: Nurturing Healthcare Through Innovative Leadership.” The article can be found here: https://insightscare.com/xiaokui-zhang-nurturing-healthcare-through-innovative-leadership/
Aspen Neuroscience Featured in the Wall Street Journal
Aspen Neuroscience is excited to be featured, and very proud of the progress we’ve made to advance the science. Thank you to the Wall Street Journal for providing focus to iPSCs. The article can be found here: https://www.wsj.com/articles/stem-cells-parkinsons-disease-heart-failure-60e9e21f?st=noc464icymdkvso&reflink=desktopwebshare_permalink
CEO Damien McDevitt, PhD, Featured in Biocom’s Article, “A Look at the Year Ahead for Life Sciences.”
Aspen Neuroscience’s CEO, Damien McDevitt, PhD, was featured in Biocom California’s article, “A Look at the Year Ahead for Life Sciences.” Damien states, “The lack of treatment options for patients with neurodegenerative diseases remains a significant unmet medical need, especially…
Kim Raineri and Andrés Bratt-Leal, PhD, presented at Phacilitate Advanced Therapies Week
Aspen Neuroscience’s Co-Founder and Senior Vice President of Research and Development, Andrés Bratt-Leal, PhD, and Chief Technology Officer, Kim Raineri, presented at the Advanced Therapies Week session, “Cell and Gene Therapy for Neurological Indications” on Friday, January 20th.
Aspen Neuroscience Selected as a Finalist for the Phacilitate Biotech Innovation Award
Aspen Neuroscience was selected as a finalist for the Biotech Innovation Award at the Advanced Therapies Awards at Phacilitate Advanced Therapies Week.
Aspen Neuroscience’s Thorsten Gorba, PhD, and Xiaokui Zhang, PhD, Presented at the iPSC-Derived Cell Therapies Summit
Aspen Neuroscience’s Chief Scientific Officer Xioakui Zhang, PhD, served as a panel member at the annual iPSC-Derived Cell Therapies Summit in Boston during “Industry Leaders’ Fireside Chat: Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies & Determining Future Outlook…
Aspen Neuroscience will Present at the Annual iPSC-Derived Cell Therapies Summit
We are looking forward to presenting this week at the annual iPSC-Derived Cell Therapies Summit in Boston. Xiaokui Zhang, PhD, Aspen’s Chief Scientific officer will serve as a panel member on Tuesday, December 6th at 8:30 a.m. during “Industry Leaders’ Fireside…
Aspen Neuroscience’s David Tastad, PhD, Presented at the Annual Society for Neuroscience Meeting
Aspen Neuroscience’s David Tastad, PhD, presented the poster “Dopamine Neuron Regulation,” at the annual Society for Neuroscience (SFN) meeting on Sunday, November 13th. The presentation explored functional characterization of GBA1 mutations in iPSC-derived midbrain dopaminergic neurons. “There was a great…